Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – NETs and endocrine tumours

5796 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Date

30 Sep 2019

Session

Poster Discussion – NETs and endocrine tumours

Presenters

Antoine Hollebecque

Citation

Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256

Authors

A. Hollebecque1, J.S. de Bono2, S. Salvagni3, R. Plummer4, N. Isambert5, P. Niccoli6, J. Capdevila7, G. Curigliano8, V. Moreno9, F.G.M. De Braud10, M. López-Brea11, P. Martin-Romano1, E. Baudin1, M. Arias12, J. de Alvaro12, J. Parra-Palau12, T. Sánchez Pérez12, E. Filvaroff13, M. Lamba14, Z. Nikolova12

Author affiliations

  • 1 Drug Development Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Department Of Medical Oncology, The Institute of Cancer Research and Royal Marsden, SW7 3RP - London/GB
  • 3 Medical Ocology, Policlinico S. Orsola Malpighi University Hospital, 40138 - Bologna/IT
  • 4 Northern Institute For Cancer Research, Newcastle University, NE2 4HH - Newcastle upon Tyne/GB
  • 5 Department Of Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 6 Medical Oncology, Insitut Paoli-Calmettes, 13009 - Marseille/FR
  • 7 Medical Oncology, Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 8 Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 9 Phase 1 Trials Unit, START Madrid - FJD, Hospital Fundación Jimenez Diaz, 28040 - Madrid/ES
  • 10 Oncology, Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 11 Medical Oncology, H.U.Marqués de Valdecilla, 39008 - Santander/ES
  • 12 Early Clinical Development, Celgene Institute Translational Research Europe-CITRE, 41092 - Sevilla/ES
  • 13 Epigenetics, Celgene Corporation, 94158 - San Francisco/US
  • 14 Medical Oncology, Celgene Corporation, 07901 - Summit/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5796

Background

CC-90011, a potent, selective, and reversible oral inhibitor of lysine-specific demethylase 1A, has shown antiproliferative activity against cancer cells in vitro and in patient (pt)-derived xenografts.

Methods

CC-90011-ST-001 is a phase I, first-in-human study of CC-90011 in ptswith advanced unresectable STs and R/R NHL. Pts received oral CC-90011 once a week (QW) in 28-d cycles. Primary endpoints included safety, maximum-tolerated dose (MTD), and/or recommended phase II dose (RP2D). Secondary objectives were to evaluate preliminary efficacy, pharmacokinetics, and pharmacodynamics (PD).

Results

As of 24 Apr2019, 64 pts with advanced STs and 1 with R/R NHL were enrolled; 25 pts had neuroendocrine neoplasms (NENs) (majority grade 3). Data presented are as of 18 Jan 2019 (n = 50). Pts received escalating doses of CC-90011 at 1.25 (n = 4), 2.5 (n = 5), 5 (n = 6), 10 (n = 4), 20 (n = 5), 40 (n = 6), 60 (n = 6), 80 (n = 10), or 120 mg (n = 4). The nontolerated dose was established as 120 mg QW, the MTD as 80 mg QW, and the RP2D as 60 mg QW. Median age was 61 y (range, 22–75), 52% were men, and pts received a median of 3 (range, 1–9) prior anticancer regimens. Thrombocytopenia, an on-target effect, was the only dose-limiting toxicity. Grade 3/4 treatment-related adverse events (AEs) were thrombocytopenia (20%), neutropenia (8%; in the context of thrombocytopenia at the highest doses), and fatigue (2%). Serious AEs occurred in 21 pts (42%); 4 (8%) were treatment-related. Peak plasma concentrations occurred 2-4 h postdose and average terminal half-life was ∼71 h; exposure was dose proportional and with repeated QW dosing, limited accumulation of plasma exposures was observed. PD analysis showed decreased CgA and MMD in response to CC-90011. One pt with R/R NHL had a complete response (CR) (currently in cycle 19); 7 pts had stable disease (SD) ≥6 mo (1 pt with bronchial NEN is currently in cycle 29).

Conclusions

CC-90011 is well tolerated with promising antitumor activity in pts with advanced malignancies, including a durable CR in R/R NHL and prolonged SD in NENs. PD data showed significant target engagement. Further evaluation of CC-90011 in combination with other agents in advanced malignancies is warranted.

Clinical trial identification

NCT02875223; CC-90011-ST-001.

Editorial acknowledgement

Tisheeka Graham-Steed, PhD BioConnections, LLC.

Legal entity responsible for the study

Celgene Corporation.

Funding

Celgene Corporation.

Disclosure

A. Hollebecque: Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Honoraria (institution): Eisai; Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: Servier; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Incyte; Advisory / Consultancy: Debiopharm; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: MedImmune. J.S. de Bono: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sierra Oncology; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Daiichi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Genmab; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: GSK; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Menarini Silicon Biosystems; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Orion; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Taiho; Research grant / Funding (institution): Cellcentric; Research grant / Funding (institution): Celgene. R. Plummer: Honoraria (self): Ellipses; Advisory / Consultancy: Pierre Faber; Advisory / Consultancy: Genmab; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Octimet; Advisory / Consultancy, Licensing / Royalties: Clovis Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Karus Therapeutics; Advisory / Consultancy: Biosceptre; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Cybrexa; Advisory / Consultancy: Sanofi Aventis; Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca; Speaker Bureau / Expert testimony: Tesaro; Travel / Accommodation / Expenses: MSD. J. Capdevila: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Advanced Accelerator Applications; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Research grant / Funding (institution): Celgene. G. Curigliano: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Honoraria (self), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Honoraria (self): Novartis; Honoraria (self): SEAGEN; Advisory / Consultancy: BMS. V. Moreno: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Regeneron; Speaker Bureau / Expert testimony: Bayer/Loxo. F.G.M. De Braud: Advisory / Consultancy: TizianaLife Sciences; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Servier; Advisory / Consultancy: Pharm Research Associated; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy, Speaker Bureau / Expert testimony: Ignyta; Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy: Octimet Oncology; Advisory / Consultancy: Incyte; Advisory / Consultancy: Teofarma; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: EMD Serono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): Loxo Oncology; Research grant / Funding (institution): Tesaro; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Gentili; Speaker Bureau / Expert testimony: Fondazione Menarini; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Noema S.r.l.; Speaker Bureau / Expert testimony: ACCMED; Speaker Bureau / Expert testimony: Dephaforum S.r.l.; Speaker Bureau / Expert testimony: Nadirex; Speaker Bureau / Expert testimony: Biotechspert Ltd; Speaker Bureau / Expert testimony: Prime Oncology. P. Martin-Romano: Research grant / Funding (institution), Non-remunerated activity/ies: AstraZeneca; Research grant / Funding (institution), Non-remunerated activity/ies: BMS; Research grant / Funding (institution), Non-remunerated activity/ies: Boehringer Ingelheim; Research grant / Funding (institution): Janssen Cilag; Research grant / Funding (institution), Non-remunerated activity/ies: Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution), Non-remunerated activity/ies: Pfizer; Research grant / Funding (institution), Non-remunerated activity/ies: Roche; Research grant / Funding (institution): Sanofi; Non-remunerated activity/ies: Bayer; Non-remunerated activity/ies: Johnson & Johnson; Non-remunerated activity/ies: Lilly; Non-remunerated activity/ies: MedImmune; Non-remunerated activity/ies: NH TherAGuiX. J. Parra-Palau: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene, Inc. T. Sánchez Pérez: Full / Part-time employment: Celgene Corp. E. Filvaroff: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Celgene; Shareholder / Stockholder / Stock options: Amgen; Shareholder / Stockholder / Stock options: Gilead; Shareholder / Stockholder / Stock options: Genentech/Roche. M. Lamba: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corp.; Licensing / Royalties: Pfizer. Z. Nikolova: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corp. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.